In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome

被引:32
作者
Chiba, K
Sugiyama, A [1 ]
Hagiwara, T
Takahashi, S
Takasuna, K
Hashimoto, K
机构
[1] Yamanashi Univ, Interdisciplinary Grad Sch Med & Engn, Dept Pharmacol, Yamanashi 4093898, Japan
[2] Daiichi Pharmaceut Co Ltd, New Prod Res Labs 2, Edogawa Ku, Tokyo 1348630, Japan
关键词
fluoroquinolone; monophasic action potential; QT interval; torsades de pointes; atrioventricular block; alpha(1)-adrenoceptor stimulation;
D O I
10.1016/j.ejphar.2003.12.014
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The proarrhythmic effects of fluoroquinolone antibacterial agents, sitafloxacin, gatifloxacin and moxifloxacin, were compared using three in vivo models. In the halothane-anesthetized dogs (n = 5), intravenous 10-min infusion of gatifloxacin and moxifloxacin (1-3 mg/kg) prolonged the ventricular effective refractory period and the repolarization period to a similar extent, whereas sitafloxacin (1-3 mg/kg) prolonged the former only. No significant change was detected in other cardiovascular parameters. In the chronic complete atrioventricular block dogs (n = 4), oral administration of 100 mg/kg of gatifloxacin (2 of 4) and moxifloxacin (3 of 4) induced torsades de pointes, which was not observed by sitafloxacin. In the alpha-chloralose-anesthetized rabbits (n = 5), intravenous 20-min infusion of 60 mg/kg of gatifloxacin induced torsades de pointes (I of 5) in the presence of methoxamine infusion, which was not observed by sitafloxacin or moxifloxacin. Thus, the halothane-anesthetized model is suitable for assessing QT prolongation, whereas the chronic complete atrioventricular block model is sensitive for detecting torsadogenic action of drugs. The alpha-chloralose-anesthetized model is the simplest and least expensive method, but its sensitivity to detect proarrhythmic action may be less great. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:189 / 200
页数:12
相关论文
共 44 条
[1]   Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials [J].
Aminimanizani, A ;
Beringer, P ;
Jelliffe, R .
CLINICAL PHARMACOKINETICS, 2001, 40 (03) :169-187
[2]  
Anderson ME, 2001, J PHARMACOL EXP THER, V296, P806
[3]  
Ball P, 2000, J ANTIMICROB CHEMOTH, V46, P17
[4]  
Bazett HC, 1920, HEART-J STUD CIRC, V7, P353
[5]   The safety profile of the fluoroquinolones [J].
Bertino, J ;
Fish, D .
CLINICAL THERAPEUTICS, 2000, 22 (07) :798-817
[6]   Gatifloxacin-associated corrected QT interval prolongation, Torsades de pointes, and ventricular fibrillation in patients with known risk factors [J].
Bertino, JS ;
Owens, RC ;
Carnes, TD ;
Iannini, PB .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (06) :861-863
[7]   Effects of fluoroquinolones on HERG currents [J].
Bischoff, U ;
Schmidt, C ;
Netzer, R ;
Pongs, O .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 406 (03) :341-343
[8]   PROARRHYTHMIC EFFECTS OF THE CLASS-III AGENT ALMOKALANT - IMPORTANCE OF INFUSION RATE, QT DISPERSION, AND EARLY AFTERDEPOLARIZATIONS [J].
CARLSSON, L ;
ABRAHAMSSON, C ;
ANDERSSON, B ;
DUKER, G ;
SCHILLERLINHARDT, G .
CARDIOVASCULAR RESEARCH, 1993, 27 (12) :2186-2193
[9]   QTU-PROLONGATION AND TORSADES-DE-POINTES INDUCED BY PUTATIVE CLASS-III ANTIARRHYTHMIC AGENTS IN THE RABBIT - ETIOLOGY AND INTERVENTIONS [J].
CARLSSON, L ;
ALMGREN, O ;
DUKER, G .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1990, 16 (02) :276-285
[10]   Proarrhythmic effects of fluoroquinolone antibacterial agents:: In vivo effects as physiologic substrate for Torsades [J].
Chiba, K ;
Sugiyama, A ;
Satoh, Y ;
Shiina, H ;
Hashimoto, K .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2000, 169 (01) :8-16